Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation reports developments in structural heart medical technology, including surgical tissue valves, transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies. Company news commonly covers the SAPIEN TAVR platform, PASCAL transcatheter edge-to-edge repair technology, the EVOQUE transcatheter tricuspid valve replacement system, and RESILIA tissue used in surgical and transcatheter valve innovations.
Recurring updates include quarterly results, clinical-trial data presented at cardiovascular meetings, reimbursement and guideline developments affecting valve procedures, product pipeline commentary, healthcare conference appearances, access initiatives for structural heart treatment, and finance leadership or governance announcements.
Edwards Lifesciences will announce its operating results for the quarter ending June 30, 2022, on July 28, 2022, after market close. A conference call to discuss the results is scheduled for 5:00 p.m. ET that day. Interested participants can join by calling (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the Investor Relations section of the Edwards website.
Edwards Lifesciences is recognized as a leader in patient-focused innovations for structural heart disease and critical care monitoring.
Edwards Lifesciences Corporation (NYSE: EW) announced its participation in the Bernstein 38th Annual Strategic Decisions Conference on June 2, 2022. CEO Michael A. Mussallem will present at 1:30 p.m. ET. The presentation will be accessible via a live webcast on the company's investor relations website, ir.edwards.com, with an archived version available later the same day. Edwards Lifesciences focuses on patient-centric innovations for structural heart disease and critical care monitoring.
Edwards Lifesciences (NYSE: EW) has announced key events at EuroPCR 2022, occurring from May 17 to 20 in Paris. Notable presentations include:
Edwards Lifesciences reported Q1 2022 results with sales of $1.34 billion, reflecting a 10% growth. TAVR sales rose 11% to $881 million. The company reaffirmed its full-year guidance for low double-digit growth despite challenges from the Omicron variant. Adjusted EPS stood at $0.60. The surgical mitral tissue valve MITRIS RESILIA received U.S. approval. The company repurchased approximately $400 million of stock. Outlook remains optimistic for 2022, with expected sales between $5.5 to $6.0 billion.
Edwards Lifesciences (NYSE: EW) will announce its operating results for Q1 2022 after market close on April 26, 2022. A conference call to discuss these results is scheduled for 5:00 p.m. ET on the same day. Edwards Lifesciences is recognized for its innovations in structural heart disease and critical care monitoring. Investors can participate by dialing (877) 704-2848 or (201) 389-0893, and the call will also be streamed live on the company’s Investor Relations webpage.
Edwards Lifesciences (NYSE: EW) has received FDA approval for the MITRIS RESILIA valve, a tissue valve designed for mitral valve replacement. This innovation features a saddle-shaped sewing cuff and a low-profile frame to minimize obstruction, facilitating future transcatheter interventions. The RESILIA tissue used in the valve has undergone extensive clinical trials, demonstrating its integrity and longevity potential. The valve is already approved in Japan, Canada, and other regions, expanding Edwards' portfolio of surgical heart valve products.
Edwards Lifesciences (NYSE: EW) reported a 19% increase in sales for 2021, totaling $5.2 billion, with Q4 sales reaching $1.33 billion, up 12%. TAVR sales hit $872 million in Q4, also up 12%. The company completed pivotal trials and received FDA approval for new products. The adjusted EPS for 2021 was $2.22, a 19% rise year-over-year. For 2022, the company expects sales between $5.5 to $6 billion and adjusted EPS of $2.50 to $2.65. Edwards anticipates significant growth in transcatheter therapies, predicting a global TAVR market expansion to $10 billion by 2028.
Edwards Lifesciences (NYSE: EW) will announce its operating results for the quarter ended December 31, 2021, after market close on January 26, 2022. The company will host a conference call at 5:00 p.m. ET that same day to discuss these results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the Investor Relations section of the Edwards website.
IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will participate in the J.P. Morgan Healthcare Conference on January 10, 2022. CEO Michael A. Mussallem is set to present virtually at 11:15 a.m. ET. A live webcast will be available on the company's investor relations website, along with an archived version later that day. Edwards Lifesciences is known for its innovations in structural heart disease and critical care monitoring.
Edwards Lifesciences has received FDA approval for the SAPIEN 3 transcatheter valve with Alterra adaptive prestent, enhancing treatment options for patients with severe pulmonary regurgitation. This innovative system combines the SAPIEN 3 valve and Alterra prestent to cater to variations in right ventricular outflow tract morphology, improving patient outcomes and reducing the need for multiple surgeries. The approval targets pediatric and adult patients requiring surgical valve replacement and is expected to significantly enhance quality of life.